Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,672 stopped studies mapped to Malignant Reproductive System Neoplasm and descendants · 89% state a reason
Over the 1,672 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06527690 | Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients…(REPRESENTATION) | Phase 2 | withdrawn | Jul 30, 2024 | Latin American Cooperative Oncology Group | The study aimed to include multiple countries in Latin America, but only Brazil was feasible,… | Enrollment / accrual |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT06516510 | A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide… | Early Phase 1 | terminated | Jul 24, 2024 | Blue Earth Therapeutics Ltd | Based on data from the Interim Analysis, the study will not adequately inform the clinical… | Safety / toxicity |
| NCT04996849 | Contemporary Characteristics of Penile Cancer | — | terminated | Aug 9, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin… | Phase 2 / Phase 3 | terminated | May 23, 2023 | Sutro Biopharma, Inc. | Due to strategic business considerations, Sutro has deprioritized the development of luveltamab… | Safety / toxicity |
| NCT06528210 | Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of… | Phase 2 | withdrawn | Jul 30, 2024 | OHSU Knight Cancer Institute | Loss of funding | Funding |
| NCT05200364 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in… | Phase 1 | terminated | Jan 20, 2022 | Sutro Biopharma, Inc. | Terminated Early | Other (stated, no rule matched) |
| NCT05445609 | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic… | Phase 2 | suspended | Jul 6, 2022 | Emory University | Per sponsor memo screening and enrollment of new patients for all ongoing Regeneron sponsored… | Enrollment / accrual |
| NCT02869282 | Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer(CHEMOPROST) | — | withdrawn | Aug 16, 2016 | Institut Bergonié | Principal investigator left the study center and nobody took over the study. | Investigator |
| NCT06058728 | A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules…(Pink Orchid) | — | withdrawn | Sep 28, 2023 | AbbVie | Company Decision | Sponsor / business decision |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT05733351 | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With… | Phase 1 | terminated | Feb 17, 2023 | Emory University | To review the safety data. | Safety / toxicity |
| NCT05820633 | Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate…(PCS-XI) | N/A | suspended | Apr 19, 2023 | CHU de Quebec-Universite Laval | amendment to be done, adding 200 patients | Other (stated, no rule matched) |
| NCT02554565 | Innovation for Standard Identification of Insertional HPV Mutations and of Target…(PAIR HPV) | N/A | terminated | Sep 18, 2015 | Institut Curie | Study in competition with another so it was decided to stop recruitment | Enrollment / accrual |
| NCT04053114 | MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii(MOLTHYSO) | — | withdrawn | Aug 12, 2019 | Institut Bergonié | Principal investigator left the investigational center and nobody took over. | Investigator |
| NCT04580667 | Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict… | — | withdrawn | Oct 8, 2020 | DiaCarta, Inc. | The sponsor declared bankruptcy | Other (stated, no rule matched) |
| NCT05092360 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With…(ARTISTRY-7) | Phase 3 | terminated | Oct 25, 2021 | Mural Oncology, Inc | Study terminated due to business and strategic decision. | Sponsor / business decision |
| NCT05708924 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Phase 1 | terminated | Feb 1, 2023 | Masonic Cancer Center, University of Minnesota | Product withdrawn from clinical development | Other (stated, no rule matched) |
| NCT06321068 | BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line… | Phase 2 / Phase 3 | terminated | Mar 20, 2024 | Bio-Thera Solutions | Due to the adjustment of our company's research and development strategy, we are now prematurely… | Sponsor / business decision |
| NCT03485794 | Collection of Blood in Studying Metabolites in Patients With Prostate Cancer | — | terminated | Apr 2, 2018 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | Phase 2 / Phase 3 | terminated | Nov 12, 2019 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With… | Phase 1 / Phase 2 | terminated | Nov 2, 2020 | Inge Marie Svane | Slow recruitment | Enrollment / accrual |
| NCT04336943 | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a… | Phase 2 | terminated | Apr 7, 2020 | University of Washington | Slow accrual | Enrollment / accrual |
| NCT05369000 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant… | Phase 1 | terminated | May 11, 2022 | Lava Therapeutics | The trial was intended to be a Phase 1/2 trial (but the trial never moved forward to Phase 2). | Other (stated, no rule matched) |
| NCT05017246 | Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural… | Phase 2 | terminated | Aug 23, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T… | — | terminated | Nov 18, 2021 | Alaunos Therapeutics | TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business… | Sponsor / business decision |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | Phase 3 | terminated | Jun 21, 2017 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT04832997 | Micro-ultrasound for Prostate Cancer Diagnosis | N/A | terminated | Apr 6, 2021 | IRCCS San Raffaele | The study faced structural and methodological obstacles, with limited enrollment, technical issues,… | Enrollment / accrual |
| NCT02140021 | Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer… | N/A | terminated | May 16, 2014 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | At the time of study termination, both fruquintinib and tislelizumab are commercially available in… | Other (stated, no rule matched) |
| NCT06655064 | Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT… | — | terminated | Oct 23, 2024 | Telix Pharmaceuticals (Innovations) Pty Limited | Sponsor request | Other (stated, no rule matched) |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT03432897 | BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects…(337) | Phase 2 | terminated | Feb 14, 2018 | Brown University | Lack of enrollment secondary to eligibility criteria | Enrollment / accrual |
| NCT04569461 | Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant…(TALON) | Phase 2 | withdrawn | Sep 29, 2020 | Duke University | Discontinuation of funding | Funding |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT03815942 | VAccination in Early and ADvanced Prostate caNCEr(ADVANCE) | Phase 1 / Phase 2 | terminated | Jan 24, 2019 | University of Oxford | COVID stopped all trials - and ADVANCE could not restart again after the pandemic | COVID-19 / pandemic |
| NCT05333432 | Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of…(HRPCa-II) | N/A | withdrawn | Apr 19, 2022 | Assistance Publique - Hôpitaux de Paris | difficulties in setting up the study within the investigation centers in connection with complex… | Other (stated, no rule matched) |
| NCT04102124 | A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC | Phase 2 | terminated | Sep 25, 2019 | Jiangsu HengRui Medicine Co., Ltd. | The sponsor's R\&D strategy is adjusted. | Sponsor / business decision |
| NCT01231932 | Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and… | — | terminated | Nov 1, 2010 | National Institute of Nursing Research (NINR) | Principal Investigator (PI) of this study is retiring. | Investigator |
| NCT04503668 | Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic… | Phase 3 | terminated | Aug 7, 2020 | University of Michigan Rogel Cancer Center | Lack of Patient Population | Other (stated, no rule matched) |
| NCT04740034 | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | Phase 1 | terminated | Feb 5, 2021 | Amgen | Sponsor strategic decision | Sponsor / business decision |
| NCT05029154 | Exercise Preconditioning in Ovarian Cancer | N/A | terminated | Aug 31, 2021 | University of Virginia | Accrual not meeting pre-specified numbers. | Enrollment / accrual |
| NCT05712174 | A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer | Phase 2 | terminated | Feb 3, 2023 | AHS Cancer Control Alberta | Accrual to the biochemically recurrent and metastatic cohorts complete; however, accrual to the… | Enrollment / accrual |
| NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent… | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03712371 | Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients | Phase 1 / Phase 2 | terminated | Oct 19, 2018 | Medical University of South Carolina | Interim study results were not favorable to continue with further enrollment. | Enrollment / accrual |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | withdrawn | May 1, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 29, 2025source: clinicaltrials